Filter Results:
(69)
Show Results For
- All HBS Web
(113)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Show Results For
- All HBS Web
(113)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Sort by
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- June 2001
- Supplement
Merck & Company: Evaluating a Drug Licensing Opportunity
Spreadsheet to (9-201-023). Download only. View Details
- November 2004
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B)
By: Lynn S. Paine
Teaching Note to (9-398-033) and (9-398-034). View Details
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- September 2001 (Revised October 2001)
- Teaching Note
Merck & Company: Evaluating A Drug Licensing Opportunity TN
By: Richard S. Ruback and Aldo Sesia
Teaching Note for (9-201-023). View Details
Keywords: Service Industry
- January 1999 (Revised March 1999)
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (B)
By: Michael Beer and James Weber
Supplements the (A) case. View Details
Keywords: United States
Beer, Michael, and James Weber. "Merck & Co., Inc.: Corporate Strategy, Organization and Culture (B)." Harvard Business School Case 499-046, January 1999. (Revised March 1999.)
- January 1994
- Case
Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc.
By: Timothy A. Luehrman
This case examines the career path of Merck's CFO, Judy C. Lewent, as a way of tracing changes over time in Merck's finance function. It describes the adoption of innovative quantitative analytical models, changes in job definitions and in the organization of the... View Details
Keywords: Finance; Mathematical Methods; Personal Development and Career; Organizational Design; Innovation and Invention; Pharmaceutical Industry
Luehrman, Timothy A. "Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc." Harvard Business School Case 294-014, January 1994.
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
- 13 Jul 2020
- Research & Ideas
Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk
As chairman and CEO of the leading vaccine producer in the world, pharmaceutical giant Merck & Co., Ken Frazier has one of the highest-profile positions in global business. But Frazier, who is leading one of the firms on a charge to... View Details
- April 1995
- Teaching Note
Evolving Finance Function, The: Judy C. Lewent at Merck & Co., Inc. (TN)
By: Timothy A. Luehrman
Teaching Note for (9-294-014). View Details
Keywords: Pharmaceutical Industry
- March 2013
- Teaching Note
Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)
By: David J. Collis
- August 2013
- Teaching Plan
Remicade-Simponi
By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson ＆ Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
- September 2010
- Case
Merck: Investing in Science-Based Business (Abridged)
By: Ananth Raman and Inga Katharina Maurer
Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless... View Details
Raman, Ananth, and Inga Katharina Maurer. "Merck: Investing in Science-Based Business (Abridged)." Harvard Business School Case 611-027, September 2010.
- 22 Nov 2004
- Research & Ideas
Side Effects: The Case of Propecia
the wives or barbers of balding men? All these issues and more faced Tom Casola, who in 1997 was heading the Propecia marketing effort for the drug maker Merck & Co. The case was discussed by audience members at the 5th Annual Alumni... View Details
- February 1998 (Revised May 1998)
- Case
Merck-Medco: Vertical Integration in the Pharmaceutical Industry
By: V. Kasturi Rangan and Marie Bell
Records the analyses and actions taken by Merck Pharmaceuticals in its acquisition of Medco, a channel intermediary (called "pharmacy benefit manager"). While many of its competitors seem to be faring poorly, Merck seems to have managed the Medco integration superbly. View Details
Keywords: Vertical Integration; Organizational Change and Adaptation; Competitive Strategy; Marketing Channels; Mergers and Acquisitions; Pharmaceutical Industry
Rangan, V. Kasturi, and Marie Bell. "Merck-Medco: Vertical Integration in the Pharmaceutical Industry." Harvard Business School Case 598-091, February 1998. (Revised May 1998.)
- 02 Nov 2020
- Working Paper Summaries
Accounting for Organizational Employment Impact
- May 2004 (Revised June 2004)
- Case
Brief Biographical Note on P. Roy Vagelos
By: Nitin Nohria and Bridget Gurtler
Provides background biographical information on P. Roy Vagelos, chief executive officer of Merck Pharmaceuticals. Teaching Purpose: To chart the development of a leader in the pharmaceutical industry. View Details
Keywords: Biography; Teaching; Leadership Development; Mission and Purpose; Personal Development and Career; Ethics; Pharmaceutical Industry
Nohria, Nitin, and Bridget Gurtler. "Brief Biographical Note on P. Roy Vagelos." Harvard Business School Case 404-132, May 2004. (Revised June 2004.)
- September 2020
- Case
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
Keywords: Vaccines; COVID-19 Pandemic; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Technological Innovation; Business Strategy; Product Launch; Pharmaceutical Industry
Shih, Willy C. "Merck: COVID-19 Vaccines." Harvard Business School Case 621-028, September 2020.
- October 2020
- Teaching Plan
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details